Long-term efficacy and safety of fluphenazine in patients with Tourette syndrome

Subhashie Wijemanne, Laura Wu, Joseph Jankovic

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Objectives: Haloperidol and pimozide are the only drugs currently approved by the U.S. Food and Drug Administration for treatment of Tourette syndrome (TS), but their potential side effects, which include tardive dyskinesia (TD), limit their use. Methods: We performed a retrospective chart review of patients with TS treated with fluphenazine over a 26-year period. Results: Among 268 patients with TS, fluphenazine was initiated at a mean age of 15.8±10.7 years (range, 4.1-70.2) and titrated to an optimal dose of 3.24±2.3 mg/day (range, 0.5-12.0), which was continued for an average of 2.6±3.2 years (range, 0.01-16.8). Marked to moderate improvement was noted in 211 (80.5%). The most common side effects included drowsiness, fatigue, or both, observed in 70 (26.1%) patients. There were no cases of TD. Conclusions: Fluphenazine appears to be safe and effective in the treatment of TS, and there were no cases of TD in this cohort treated up to 16.8 years.

Original languageEnglish (US)
Pages (from-to)126-130
Number of pages5
JournalMovement Disorders
Volume29
Issue number1
DOIs
StatePublished - Jan 2014
Externally publishedYes

Fingerprint

Fluphenazine
Tourette Syndrome
Safety
Pimozide
Sleep Stages
Haloperidol
United States Food and Drug Administration
Fatigue
Therapeutics
Pharmaceutical Preparations
Tardive Dyskinesia

Keywords

  • Fluphenazine
  • Side effects
  • Tardive dyskinesia
  • Tics
  • Tourette syndrome

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Long-term efficacy and safety of fluphenazine in patients with Tourette syndrome. / Wijemanne, Subhashie; Wu, Laura; Jankovic, Joseph.

In: Movement Disorders, Vol. 29, No. 1, 01.2014, p. 126-130.

Research output: Contribution to journalArticle

Wijemanne, Subhashie ; Wu, Laura ; Jankovic, Joseph. / Long-term efficacy and safety of fluphenazine in patients with Tourette syndrome. In: Movement Disorders. 2014 ; Vol. 29, No. 1. pp. 126-130.
@article{e59bcc92a35f4238b85bcb89afa1adb7,
title = "Long-term efficacy and safety of fluphenazine in patients with Tourette syndrome",
abstract = "Objectives: Haloperidol and pimozide are the only drugs currently approved by the U.S. Food and Drug Administration for treatment of Tourette syndrome (TS), but their potential side effects, which include tardive dyskinesia (TD), limit their use. Methods: We performed a retrospective chart review of patients with TS treated with fluphenazine over a 26-year period. Results: Among 268 patients with TS, fluphenazine was initiated at a mean age of 15.8±10.7 years (range, 4.1-70.2) and titrated to an optimal dose of 3.24±2.3 mg/day (range, 0.5-12.0), which was continued for an average of 2.6±3.2 years (range, 0.01-16.8). Marked to moderate improvement was noted in 211 (80.5{\%}). The most common side effects included drowsiness, fatigue, or both, observed in 70 (26.1{\%}) patients. There were no cases of TD. Conclusions: Fluphenazine appears to be safe and effective in the treatment of TS, and there were no cases of TD in this cohort treated up to 16.8 years.",
keywords = "Fluphenazine, Side effects, Tardive dyskinesia, Tics, Tourette syndrome",
author = "Subhashie Wijemanne and Laura Wu and Joseph Jankovic",
year = "2014",
month = "1",
doi = "10.1002/mds.25692",
language = "English (US)",
volume = "29",
pages = "126--130",
journal = "Movement Disorders",
issn = "0885-3185",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

TY - JOUR

T1 - Long-term efficacy and safety of fluphenazine in patients with Tourette syndrome

AU - Wijemanne, Subhashie

AU - Wu, Laura

AU - Jankovic, Joseph

PY - 2014/1

Y1 - 2014/1

N2 - Objectives: Haloperidol and pimozide are the only drugs currently approved by the U.S. Food and Drug Administration for treatment of Tourette syndrome (TS), but their potential side effects, which include tardive dyskinesia (TD), limit their use. Methods: We performed a retrospective chart review of patients with TS treated with fluphenazine over a 26-year period. Results: Among 268 patients with TS, fluphenazine was initiated at a mean age of 15.8±10.7 years (range, 4.1-70.2) and titrated to an optimal dose of 3.24±2.3 mg/day (range, 0.5-12.0), which was continued for an average of 2.6±3.2 years (range, 0.01-16.8). Marked to moderate improvement was noted in 211 (80.5%). The most common side effects included drowsiness, fatigue, or both, observed in 70 (26.1%) patients. There were no cases of TD. Conclusions: Fluphenazine appears to be safe and effective in the treatment of TS, and there were no cases of TD in this cohort treated up to 16.8 years.

AB - Objectives: Haloperidol and pimozide are the only drugs currently approved by the U.S. Food and Drug Administration for treatment of Tourette syndrome (TS), but their potential side effects, which include tardive dyskinesia (TD), limit their use. Methods: We performed a retrospective chart review of patients with TS treated with fluphenazine over a 26-year period. Results: Among 268 patients with TS, fluphenazine was initiated at a mean age of 15.8±10.7 years (range, 4.1-70.2) and titrated to an optimal dose of 3.24±2.3 mg/day (range, 0.5-12.0), which was continued for an average of 2.6±3.2 years (range, 0.01-16.8). Marked to moderate improvement was noted in 211 (80.5%). The most common side effects included drowsiness, fatigue, or both, observed in 70 (26.1%) patients. There were no cases of TD. Conclusions: Fluphenazine appears to be safe and effective in the treatment of TS, and there were no cases of TD in this cohort treated up to 16.8 years.

KW - Fluphenazine

KW - Side effects

KW - Tardive dyskinesia

KW - Tics

KW - Tourette syndrome

UR - http://www.scopus.com/inward/record.url?scp=84892938510&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892938510&partnerID=8YFLogxK

U2 - 10.1002/mds.25692

DO - 10.1002/mds.25692

M3 - Article

C2 - 24150997

AN - SCOPUS:84892938510

VL - 29

SP - 126

EP - 130

JO - Movement Disorders

JF - Movement Disorders

SN - 0885-3185

IS - 1

ER -